The antibody-drug conjugate trastuzumab emtansine (TDM-1) represents a further advancement to treat metastatic HER2-positive BC with significant activity in both asymptomatic and symptomatic BM [167,168,169], but little is known regarding its efficacy in LM. Here, ERBB2 is linked to breast cancer.